Alexion Overview

  • Founded
  • 1992
Founded
  • Status
  • Public
  • Employees
  • 3,837
Employees
  • Stock Symbol
  • ALXN
Stock Symbol
  • Investments
  • 22
  • Share Price
  • $171.41
  • (As of Tuesday Closing)

Alexion General Information

Description

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.

Contact Information

Website
www.alexion.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
NAS
Primary Office
  • 121 Seaport Boulevard
  • Boston, MA 02210
  • United States
+1 (475) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Alexion Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$171.41 $171.81 $98.89 - $172.59 $37.9B 221M 2.41M $3.14

Alexion Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 33,356,652 34,643,701 24,416,988 23,391,288
Revenue 6,261,600 6,069,900 4,991,100 4,131,200
EBITDA 929,700 1,003,100 2,633,400 745,700
Net Income 681,800 603,400 2,404,300 77,600
Total Assets 18,650,200 18,103,000 17,544,600 13,931,900
Total Debt 2,702,800 2,739,100 2,665,800 3,206,500
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alexion Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alexion‘s full profile, request access.

Request a free trial

Alexion Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its
Pharmaceuticals
Boston, MA
3,837 As of 2020
000 0000-00-00
000000&0

00000000

, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut
00000000000 0000000
San Rafael, CA
0000 As of 0000
00000
0000 00000

0000 000

quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure
000000000000000
Dublin, Ireland
0000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alexion Competitors (53)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioMarin Pharmaceutical Formerly PE-Backed San Rafael, CA 0000 00000 0000 00000
0000 0000000000000 Formerly VC-backed Dublin, Ireland 0000 00000 000000 - 000 00000
00000 Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
000000 Formerly VC-backed Cambridge, MA 0000 000.00 00000000000 000.00
000000000 00000000 Formerly VC-backed Tarrytown, NY 0000 00000 00000000000 00000
You’re viewing 5 of 53 competitors. Get the full list »

Alexion Executive Team (42)

Name Title Board Seat Contact Info
Ludwig Hantson Ph.D Chief Executive Officer & Board Member
Aradhana Sarin Chief Financial Officer, Finance & Executive Vice President
Daniel Bazarko Senior Vice President, Finance & Chief Accounting Officer
Indrani Franchini JD Executive Vice President & Chief Compliance Officer, Legal
Uzair Qadeer Chief Diversity Officer
You’re viewing 5 of 42 executive team members. Get the full list »

Alexion Board Members (13)

Name Representing Role Since
Andreas Rummelt Ph.D Self Board Member 000 0000
Christopher Coughlin Self Board Member 000 0000
David Brennan Alexion Chairman & Board Member 000 0000
Deborah Dunsire MD Self Board Member 000 0000
Francois Nader Ph.D Self Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Alexion Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alexion Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Alexion‘s full profile, request access.

Request a free trial

Alexion Investments & Acquisitions (22)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 00000000000 05-Jan-2021 000000000 00000 00 00000 Buildings and Property 00000000 00000
0000000 0000000000 02-Jul-2020 000000000000000000 00.000 Pharmaceuticals 000000 0000000 00.0
000000000 28-Jan-2020 000000000000000000 00000 Pharmaceuticals 000000 0000000 00.0
000000 00000000000 21-Nov-2019 000000000 00000 00 000 Buildings and Property
Eidos Therapeutics 09-Sep-2019 PIPE 0000 Drug Discovery 0000 000000 00
You’re viewing 5 of 22 investments and acquisitions. Get the full list »

Alexion Subsidiaries (2)

Company Name Industry Location Founded
Complement Pharma Drug Discovery Amsterdam, Netherlands 2009
0000000 0000000000 Pharmaceuticals South San Francisco, CA 0000
To view Alexion’s complete subsidiaries history, request access »

Alexion Exits (4)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000 000000000000 09-Sep-2019 0000 0000 Completed
  • 0000000
0000000 0000000000 05-Jan-2015 00000 00000 00 00000 Completed
  • 9 buyers
0000000 0000000000 22-Jan-2014 00000 00000 00 00000 Completed
  • 4 buyers
PhaseRx 02-Oct-2013 Convertible Debt 00.00 Completed
To view Alexion’s complete exits history, request access »